The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials.
The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials.
复制标题
DOI：
10.1093/nar/gkab1010
复制
发表时间：
2022-01-07
影响因子：
14.9
通讯作者：
NC-IUPHAR
中科院分区：
文献类型：
--
作者：
Harding SD;Armstrong JF;Faccenda E;Southan C;Alexander SPH;Davenport AP;Pawson AJ;Spedding M;Davies JA;NC-IUPHAR
IUPHAR/BPS药理学指南（GtoPdb; www.guidetopharmacology.org）是一个开放获取的，专家策划的配体及其靶标之间分子相互作用的数据库。我们描述了在过去两年中发布的9个数据库的内容扩展，主要集中在三个主要的感染领域。2019冠状病毒病大流行继续对全球健康产生重大影响。GtoPdb寻求支持更广泛的研究界，以了解新出现的针对SARS-CoV-2的药物靶点的药理学，以及宿主中阻止病毒进入和减少COVID-19患者感染的不良影响的潜在靶点。我们描述了该数据库如何快速发展，以包括一个新的冠状病毒蛋白家族。疟疾仍然是对世界一半人口的全球性威胁。我们的数据库内容通过我们与疟疾药物企业（MMV）在IUPHAR/MMV疟疾药理学指南（www.guidetomalariapharmacology.org）上的合作继续得到加强。抗生素耐药性也是对全球健康日益严重的威胁。作为回应，我们扩大了与抗生素db合作的抗生素覆盖范围。
The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; www.guidetopharmacology.org) is an open-access, expert-curated database of molecular interactions between ligands and their targets. We describe expansion in content over nine database releases made during the last two years, which has focussed on three main areas of infection. The COVID-19 pandemic continues to have a major impact on health worldwide. GtoPdb has sought to support the wider research community to understand the pharmacology of emerging drug targets for SARS-CoV-2 as well as potential targets in the host to block viral entry and reduce the adverse effects of infection in patients with COVID-19. We describe how the database rapidly evolved to include a new family of Coronavirus proteins. Malaria remains a global threat to half the population of the world. Our database content continues to be enhanced through our collaboration with Medicines for Malaria Venture (MMV) on the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY (www.guidetomalariapharmacology.org). Antibiotic resistance is also a growing threat to global health. In response, we have extended our coverage of antibacterials in partnership with AntibioticDB.
登录
查看更多内容
影响因子：
14.9
作者：
Avram S;Bologa CG;Holmes J;Bocci G;Wilson TB;Nguyen DT;Curpan R;Halip L;Bora A;Yang JJ;Knockel J;Sirimulla S;Ursu O;Oprea TI
通讯作者：
Oprea TI
影响因子：
14.9
作者：
Harmar AJ;Hills RA;Rosser EM;Jones M;Buneman OP;Dunbar DR;Greenhill SD;Hale VA;Sharman JL;Bonner TI;Catterall WA;Davenport AP;Delagrange P;Dollery CT;Foord SM;Gutman GA;Laudet V;Neubig RR;Ohlstein EH;Olsen RW;Peters J;Pin JP;Ruffolo RR;Searls DB;Wright MW;Spedding M
通讯作者：
Spedding M
影响因子：
64.8
作者：
Jumper J;Evans R;Pritzel A;Green T;Figurnov M;Ronneberger O;Tunyasuvunakool K;Bates R;Žídek A;Potapenko A;Bridgland A;Meyer C;Kohl SAA;Ballard AJ;Cowie A;Romera-Paredes B;Nikolov S;Jain R;Adler J;Back T;Petersen S;Reiman D;Clancy E;Zielinski M;Steinegger M;Pacholska M;Berghammer T;Bodenstein S;Silver D;Vinyals O;Senior AW;Kavukcuoglu K;Kohli P;Hassabis D
通讯作者：
Hassabis D
影响因子：
9.6
作者：
Yang T;Ottilie S;Istvan ES;Godinez-Macias KP;Lukens AK;Baragaña B;Campo B;Walpole C;Niles JC;Chibale K;Dechering KJ;Llinás M;Lee MCS;Kato N;Wyllie S;McNamara CW;Gamo FJ;Burrows J;Fidock DA;Goldberg DE;Gilbert IH;Wirth DF;Winzeler EA;Malaria Drug Accelerator Consortium
通讯作者：
Malaria Drug Accelerator Consortium
影响因子：
14.9
作者：
Kim S;Chen J;Cheng T;Gindulyte A;He J;He S;Li Q;Shoemaker BA;Thiessen PA;Yu B;Zaslavsky L;Zhang J;Bolton EE
通讯作者：
Bolton EE